ACADIA Pharmaceuticals Inc. (ACAD)

US — Healthcare Sector
Peers: ADMA  PRAX  LGND  BLTE  SLNO  MIRM  CRNX  DYN  VKTX  IMVT 

Automate Your Wheel Strategy on ACAD

With Tiblio's Option Bot, you can configure your own wheel strategy including ACAD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ACAD
  • Rev/Share 6.071
  • Book/Share 4.9002
  • PB 5.5427
  • Debt/Equity 0.0685
  • CurrentRatio 2.9106
  • ROIC 0.2137

 

  • MktCap 4594574824.0
  • FreeCF/Share 1.1148
  • PFCF 24.5586
  • PE 20.5176
  • Debt/Assets 0.0459
  • DivYield 0
  • ROE 0.3067

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 4
  • P/B Score 2
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ACAD Citigroup -- Buy -- $33 Oct. 21, 2025
Upgrade ACAD Deutsche Bank Hold Buy -- $35 May 21, 2025
Initiation ACAD Deutsche Bank -- Hold -- $22 Feb. 11, 2025
Downgrade ACAD Guggenheim Buy Neutral $23 $20 Jan. 3, 2025
Resumed ACAD Raymond James -- Market Perform -- -- Oct. 10, 2024

News

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
ACAD
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative

ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.

Read More
image for news Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript
ACAD
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q4 2024 Results Conference Call February 26, 2025 4:30 PM ET Company Participants Al Kildani - SVP of Investor Relations & Corporate Communications Catherine Owen Adams - CEO Tom Garner - COO Elizabeth Thompson - EVP, Head of R&D Mark Schneyer - EVP, CFO Conference Call Participants Ami Fadia - Needham & Company Tessa Romero - JPMorgan Joel Beatty - Baird Tazeen Ahmad - Bank of America Securities Gregory Renza - RBC Capital Markets Charles Duncan - Cantor Sumant Kulkarni - Canaccord Genuity LLC Operator Good day, ladies and gentlemen, and welcome to the ACADIA …

Read More
image for news ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

About ACADIA Pharmaceuticals Inc. (ACAD)

  • IPO Date 2004-05-27
  • Website https://www.acadia-pharm.com
  • Industry Biotechnology
  • CEO Catherine E. Owen Adams
  • Employees 653
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.